The development of a semisynthetic diet deficient in methionine for adult cats for controlled feline nutrition studies: effects on acceptability, preference, and behavior responses

Article

Author: Dancy, Kaitlyn ; Shoveller, Anna K ; Pezzali, Julia Guazzelli ; Bullerwell, Asha ; DeVries, Trevor J

AbstractChemically defined diets are commonly used in amino acid (AA) requirement studies to allow for tight control of AA delivery. However, those diets are not representative of commercial diets in the market and are unpalatable. Methionine (Met) is usually the first limiting AA in cat diets, but little is known about its requirement for adult cats. Thus, the objectives of this study were: 1) to develop a semisynthetic diet limiting in Met and evaluate its effect on acceptance and feeding behavior in cats; and 2) to evaluate the effect of different sources and inclusions of Met on preference in cats fed the semisynthetic diet. A semisynthetic diet deficient in Met and total sulfur AA (TSAA) was developed. Healthy adult male cats (n = 9) were fed (0800 and 1600 h) the semisynthetic diet top dressed with DL-Met solution (T-DLM), to meet 120% of the TSAA requirement, for 8 d. Feed intake was measured and a 30-min video recording was taken at the 0800 h feeding to evaluate feeding behavior of the cats. Following the acceptability trial, two bowl tests were performed where first choice was recorded and intake ratio was calculated as consumed food (A/A + B). Three combinations were tested: semisynthetic diet deficient in Met (T-BASAL) vs. T-DLM; T-BASAL vs. diet sufficient in Met provided 2-hydroxy-4-(methylthio)-butanoic acid (T-MHA); and T-DLM vs. T-MHA. Average feed intake remained high throughout the acceptability period (94.5% intake of total offered), but some cats decreased intake, resulting in a decrease in BW (≤2.5% of initial BW) over time (P < 0.05). Behaviors were similar among days (P > 0.05) with the exception of grooming the chest and body (P < 0.05). No preferences were observed towards a specific treatment (Met source and level) during the two-bowl tests (P > 0.05) and agreed with the cats expressing similar feeding behaviors during the preference tests (P > 0.05). In conclusion, a semisynthetic diet deficient in Met was successfully developed and can be used in studies to evaluate the effects of low protein and AA supplemented diets. Cats seem to show no preference for Met source and/or inclusion level in a semisynthetic diet application, which is of benefit for future studies aiming to determine the Met requirement in this species.

03 Jan 2023·Journal of Animal Science

Applying the indicator amino acid oxidation technique in the domestic cat: results of a pilot study and development of a non-steady state prediction model

Article

Author: Rafii, Mahroukh ; Shoveller, Anna K ; Courtney-Martin, Glenda ; Pezzali, Julia Guazzelli ; Cant, John P

AbstractThe aim of this study was to evaluate whether the indicator amino acid oxidation (IAAO) method could be applied in the domestic cat. Six adult male cats were used in a replicated 3 × 3 Latin square design. Three semi-synthetic diets were developed: a methionine (Met) and total sulfur AA (TSAA) deficient diet (T-BASAL; 0.24% Met+Cys − DM basis) and two Met and TSAA-sufficient diets in which either dl-Met (T-DLM) or 2-hydroxy-4-(methylthio)-butanoic acid (T-MHA) were supplemented, respectively, on an equimolar basis to meet the TSAA requirement (0.34%). After a 2-d diet adaptation, IAAO studies were performed. Cats were offered 13 small meals. The sixth meal contained a priming dose (4.8 mg/kg-BW) of l-[1-13C]-Phe and the remaining meals a constant dose (1.04 mg/kg-BW). Breath samples were collected every 25 min to measure 13CO2 enrichment. The following morning, fasted blood samples were collected. Cats returned to the T-BASAL top dressed with a dl-Met solution for 4 d prior to being fed a new dietary treatment. Isotopic steady state was evaluated through visual inspection. Data were analyzed using PROC GLIMMIX procedure in SAS 9.4. While 13CO2 enrichment was successfully captured in breath samples, cats failed to reach 13CO2 steady state. Thus, a non-steady state isotope model was developed and coded in ACSLX (V3.1.4.2) individually for each cat on each study day to predict 13CO2 enrichment, and then, calculate oxidation of l-[1-13C]-Phe (F13CO2). A higher predicted F13CO2 was observed for cats fed T-BASAL compared to the others (P < 0.05), while no differences were observed between T-DLM and T-MHA (P > 0.05). Cats fed T-DLM tended to have higher plasma Met concentrations compared to those fed T-BASAL with cats fed T-MHA intermediate (P = 0.0867). Plasma homocysteine concentrations were higher in cats fed T-BASAL compared to the others (P < 0.05), while threonine concentrations tended to be higher in cats fed T-BASAL compared to those fed T-MHA (P = 0.0750). In conclusion, short-term provision of a semi-synthetic diet deficient in Met may elicit a metabolic response aiming to conserve Met. The successful quantification of 13CO2 enrichment in breath and the higher predicted F13CO2 in cats fed a Met deficient diet suggest that the IAAO technique may be used in cats. Adaptations in the isotope protocol should be made to achieve 13CO2 steady state in breath and avoid mathematical modeling to predict F13CO2.

10 Feb 2021·Science Translational MedicineQ1 · MEDICINE

Targeted immunotherapy for HER2-low breast cancer with 17p loss

Q1 · MEDICINE

Article

Author: Lu, Xiongbin ; Sun, Yifan ; Kulke, Michael ; Dong, Tianhan ; Li, Yujing ; Radovich, Milan ; Zhang, Xinna ; Schneider, Bryan P. ; Van der Jeught, Kevin ; Hechler, Torsten ; Miller, Kathy D. ; He, Bin ; Pahl, Andreas

Trastuzumab conjugated to α-amanitin kills HER2-low breast cancer cells with loss of chromosome 17p and enhances checkpoint blockade therapy.

100 Deals associated with T-Ama

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HER2-Low Breast Carcinoma	Preclinical	United States	Indiana University	09 Feb 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

T-Ama

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation